GMABGenmabRunning, no new patients
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 379 (final count)
- Started
- Aug 13, 2024
- Main results expected
- Mar 2028
- Fully finished
- Mar 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Arm A vs Arm B: Progression-Free Survival (PFS)
Measured over: Up to 4 Years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06508658 · record last updated 2026-04-08 · checked 2026-11-09 15:47 UTC